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The unchecked overproduction of reactive oxygen and
nitrogen species by inflammatory cells can cause tissue
damage, intensify inflammation, promote apoptosis,
and accelerate the progression of immune-mediated
glomerulonephritis (GN). Here we tested whether the
anti-inflammatory and antioxidant properties of the green
tea polyphenol ()-epigallocatechin-3-gallate (EGCG)
favorably affect the development of immune-mediated GN.
Pretreatment of 129/svJ mice with EGCG from 2 days before
to 2 weeks after the induction of GN led to reduced
proteinuria and serum creatinine, and marked improvement
in renal histology when compared with vehicle-pretreated
diseased mice. This pretreatment reduced oxidative stress,
and normalized osteopontin, p65/nuclear factor-jB, inducible
nitric oxide synthase, nitric oxide metabolites, p-Akt,
phosphorylated extracellular signal-regulated kinases 1 and
2, p47phox, and myeloperoxidase, all of which were elevated
in vehicle-pretreated diseased mice. Levels of glutathione
peroxidase and peroxisome proliferator-activated receptor-c
(PPARc), both reduced in the vehicle-pretreated diseased
mice, were normalized. This renoprotective effect was
reversed by concomitant administration of the PPARc
antagonist GW9662 throughout the EGCG pretreatment
period. Importantly, mortality and renal dysfunction were
significantly attenuated even when the polyphenol
treatment was initiated 1 week after the onset of GN.
Thus, EGCG reversed the progression of immune-mediated
GN in mice by targeting redox and inflammatory
pathways.
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Anti-glomerular basement membrane antibody-induced
glomerulonephritis (anti-GBM-GN) is pathologically and
clinically the most severe form of immune-mediated GN.
It is caused by circulating antibodies directed to the GBM
components, non-collagenous-1 domain of the a3 or a5
chain of type IV collagen, leading to an inflammatory reac-
tion in the glomerular capillaries.1–4 The treatment of anti-
GBM-GN aims to modulate the injury-causing immunologic
process with high-dose corticosteroids, cytotoxic drugs, and
plasmapheresis. However, end-stage renal disease develops in
40–70% of patients.4,5
Reactive oxygen species (ROS) are products of normal
cellular metabolism that modulate physiological functions
and affect innate immunity in infectious and noninfectious
inflammation.6 However, unchecked overproduction of ROS,
reactive nitrogen species, and reactive chlorine species by
inflammatory cells can cause further tissue damage, intensify
inflammation, promote apoptosis, and accelerate progression
of many diseases including anti-GBM-GN.7,8 In physiologic
condition, superoxide dismutase (SOD) catalyzes superoxide
to molecular oxygen and hydrogen peroxide (H2O2). H2O2 is
degraded to water and molecular oxygen by catalase or by
glutathione peroxidase (GPx) in the presence of reduced
glutathione. However, in the presence of electron donors such
as iron, H2O2 is converted to hydroxyl radical, which is the
most reactive and cytotoxic ROS. Additionally, myeloper-
oxidase (MPO), expressed in neutrophils and macrophages,
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converts H2O2 to hypochlorous acid, a highly cytotoxic
reactive chlorine species. Finally, H2O2 is an activator of
nuclear factor-kB (NF-kB), a master regulator of pro-
inflammatory cytokines, chemokines, and fibrogenic factors.
Superoxide reacts with nitric oxide (NO) to produce
peroxynitrite, a highly reactive nitrogen species. Excessive
production and impaired capacity of the antioxidant system
to inactivate superoxide and H2O2 play a central role in the
pathogenesis of glomerular injury, hyperpermeability, and
worsening of inflammatory glomerular disease.9
The green tea catechins, particularly ()-epigallocatechin-
3-gallate (EGCG), are potent anti-inflammatory and anti-
oxidant agents shown to inhibit leukocyte chemotaxis,
quench free radicals, chelate transition metals, and interrupt
lipid peroxidation chain reaction.10–13 EGCG is estimated to
be 25 times more potent than vitamin E and 100 times more
potent than vitamin C.14 However, the effect of EGCG on
immune-mediated renal injury has not been investigated.
We tested the hypothesis that the anti-inflammatory and
antioxidant properties of EGCG favorably affect the course
of immune-mediated GN using a murine model of anti-
GBM-GN. Here, we show that the EGCG administration
significantly improves the laboratory and histopathological
features of anti-GBM-GN.
RESULTS
EGCG attenuated the development of anti-GBM-GN
General data and biochemical/immunological measurements.
At the end of the 2-week observation period, the vehicle-
pretreated mice with anti-GBM-GN developed weight
loss, renal insufficiency, and proteinuria in contrast to the
normal controls. No mice died of disease during the course of
the study. EGCG pretreatment led to significantly less
proteinuria and normalized serum creatinine compared
with the vehicle-pretreated mice (Table 1). The levels of
immunoglobulin G (IgG) mouse anti-rabbit antibodies
were comparable between the two groups of mice with
anti-GBM-GN, indicating that the reduced renal disease in
EGCG-pretreated mice was not caused by a decreased
xenogenic immune response to the injected immunoglobulin
(Figure 1).
Renal histology. The vehicle-pretreated mice showed
moderate to severe renal injury characterized by crescent
formation with marked intracapillary hypercellularity, obli-
terated capillary lumens, and thickened capillary walls
(Table 1 and Figure 2). Tubular atrophy and dilation with
hyaline casts and interstitial fibrosis were also noted. In
comparison, the EGCG-pretreated mice exhibited milder
renal injury with occasional crescent formation, and focal
tubulointerstitial injury. No lesions were seen in the normal
control group. In addition, both glomerular and interstitial
Table 1 | General data and renal injuries in EGCG- and vehicle-pretreated mice with anti-GBM-GN and in normal controls
Control Anti-GBM/vehicle Anti-GBM/EGCG
Body weight (g) 20.2±0.4 17.0±0.5** 19.1±0.5##
Serum creatinine (mg/dl) 0.09±0.01 0.15±0.01** 0.10±0.01##
Proteinuria (mg per 24 h) 0.78±0.08 12.68±1.45** 5.11±1.01**,##
Glomerulonephritis score (0–4) 0±0 3.5±0.2** 2.0±0.4*,#
Crescents (%) 0±0 22.8±4.2** 6.5±3.3**,##
Tubulointerstitial injury score (0–5) 0±0 2.4±0.2** 1.2±0.3**,##
Macrophage infiltration
Glomeruli (cells per 50 glomerular cross-section) 1.4±0.8 112.0±20.6** 8.7±3.8*,##
Interstitial (cells per 10 high-power field) 50.5±7.2 520.3±82.7** 132.3±30.0*,##
Lymphocyte infiltration
Glomeruli (cells per 50 glomerular cross-section) 1.9±0.6 19.2±8.4** 3.2±0.8##
Interstitial (cells per 10 high power field) 3.8±1.1 45.1±10.2** 7.5±3.6##
Abbreviations: Anti-GBM/EGCG, anti-glomerular basement membrane antibody-induced glomerulonephritis pretreated with ()-epigallocatechin-3-gallate; anti-GBM/vehicle,
anti-glomerular basement membrane antibody-induced glomerulonephritis pretreated with vehicle; GN, glomerulonephritis.
Values are mean±s.e.m.; n=14 in each group.
*Po0.05, **Po0.01 vs control.
#Po0.05, ##Po0.01 vs anti-GBM/vehicle.
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Figure 1 |Anti-rabbit immunoglobulin (Ig) response in
()-epigallocatechin-3-gallate (EGCG)- or vehicle-pretreated
mice with anti-glomerular basement membrane antibody-
induced glomerulonephritis (anti-GBM-GN). Depicted are the
serum levels of IgG mouse anti-rabbit antibodies (measured
on day 14) assayed in serial dilutions. Values are expressed as
mean±s.e.m. n¼ 7 in each group.
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infiltrations by macrophages and lymphocytes were signifi-
cantly higher in the vehicle-pretreated mice compared with
both the EGCG-pretreated mice and normal controls (Figure 2
and Table 1).
Markers of oxidative and nitrosative stress. Renal tissue and
urine malondialdehyde (MDA) levels were modestly higher
in the vehicle-pretreated mice than the normal control group.
EGCG pretreatment normalized the MDA levels in both renal
tissue and urine. Serum MDA levels were not significantly
different among the three groups (Figure 3).
Renal tissue and urine H2O2 levels were significantly
higher in the vehicle-pretreated mice than the normal control
group, whereas serum H2O2 levels were not significantly
different. Compared with the vehicle-pretreated mice, EGCG
pretreatment significantly lowered H2O2 levels in renal tissue,
urine, and serum (Figure 3).
Immunohistochemistry showed diffuse and strong nitro-
tyrosine staining in proximal and distal convoluted tubules
(4þ ), glomerular cells (3þ ), and interlobular vascular
endothelium (3þ ) of the vehicle-pretreated mice. The
nitrotyrosine staining pattern and intensity were similar in
the EGCG-pretreated mice, but the staining was weaker in
the normal control mice. Similar results were obtained with
western blot performed on kidney tissues. Renal tissues of the
vehicle- and EGCG-pretreated mice had significantly higher
nitrotyrosine than normal controls. Renal tissue nitrotyrosine
abundance was not significantly different between the
vehicle- and EGCG-pretreated mice (Figure 3).
NO pathway. Western blot showed similar levels of renal
endothelial nitric oxide synthase (eNOS) expression in the
three groups of mice (Figure 4). In contrast, inducible nitric
oxide synthase (iNOS) protein content of renal tissue was
significantly higher in the vehicle-pretreated animals than
both the normal control and EGCG-pretreated groups. Total
NO metabolite (nitratesþ nitrites) content in kidney, urine,
and serum was significantly higher in the vehicle-pretreated
mice than the normal controls. EGCG pretreatment norma-
lized the total NO metabolite levels in kidney, urine, and
serum (Figure 4).
ROS-generating and antioxidant enzymes. Western blot
analysis showed significantly higher expression of nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase
regulatory subunit p47phox in the vehicle-pretreated
mice compared with both normal control and EGCG-
pretreated mice, pointing to the increased ROS production
in the vehicle-pretreated anti-GBM-GN mice (Figure 5). The
expression of SOD-1 was modestly elevated in the vehicle-
pretreated mice compared with the normal control mice
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Figure 2 |Renal histology and immunohistochemical analysis of ()-epigallocatechin-3-gallate (EGCG)- or vehicle-pretreated mice
with anti-glomerular basement membrane antibody-induced glomerulonephritis (anti-GBM-GN). Kidneys from mice 2 weeks after
induction of anti-GBM-GN with or without EGCG pretreatment and kidneys from normal control mice were evaluated by light microscopy.
In the periodic acid-Schiff (PAS)-stained section, the kidneys in the vehicle-pretreated mice revealed severe glomerular hypercellularity
with large crescent. There were also significant tubular atrophy and interstitial fibrosis with prominent interstitial inflammatory infiltrates
(original magnification  400). Immunohistochemical analyses showed markedly increased interstitial infiltration of lymphocytes and
macrophages in the vehicle-pretreated group (original magnification  400). In contrast, the EGCG-pretreated animals exhibited mild to
moderate glomerular injury with minimal crescent formation and focal mild tubulointerstitial injury. No significant histopathological
changes were observed in the normal control group.
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(Figure 5). This phenomenon points to a biological response
to the prevailing oxidative stress in the renal tissue. EGCG
pretreatment further elevated the renal SOD-1 abundance
(Figure 5). The renal tissue GPx1 expression was significantly
lower in the vehicle-pretreated mice than both the normal
control and EGCG-pretreated mice. Western blot showed
significantly higher MPO in the vehicle-pretreated mice than
both the normal control and EGCG-pretreated mice; the
MPO levels in the latter two groups were comparable.
There was no significant difference in the expressions of
heme oxygenase-1 (HO-1) among the three groups (Figure 5).
The renal tissue catalase activity was significantly lower in
the vehicle-pretreated mice than both the normal control and
EGCG-pretreated mice (Figure 5).
Molecules associated with inflammatory pathways. Immuno-
histochemistry showed diffuse and strong staining for osteo-
pontin (OPN) in virtually all proximal and distal renal
tubules (4þ ) of the vehicle-pretreated mice (Figure 6). The
glomeruli showed positive staining for OPN in parietal
epithelial cells (2þ ), scattered podocytes (3þ ), and infil-
trating leukocytes (4þ ). Numerous interstitial macrophages
were also strongly positive (4þ ). In the EGCG-pretreated
mice, mild OPN expression was noted in occasional
glomerular parietal epithelial cells (1þ ), distal tubules
(1þ ), and interstitial infiltrating cells (1þ ). No significant
glomerular or tubulointerstitial OPN staining was observed
in the normal control mice. Western blot confirmed the
immunohistochemical results, with significantly higher renal
OPN expression in the vehicle-pretreated mice than both
the EGCG-pretreated and normal control mice (Figure 6).
Immunohistochemistry showed diffuse and strong stain-
ing for p65/NF-kB in nearly all proximal and distal renal
tubules (4þ ) of the vehicle-pretreated anti-GBM-GN mice
(Figure 6). Additionally, many glomerular infiltrating leuko-
cytes and resident cells (3þ ) and interstitial macrophages
(3þ ) were positive for p65/NF-kB. The staining was
localized to both cytoplasm and nucleus, the latter signifying
NF-kB activation. Conversely, in the EGCG-pretreated mice,
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Figure 3 |Malondialdehyde (MDA), hydrogen peroxide (H2O2), and nitrotyrosine in mice with anti-glomerular basement membrane
antibody-induced glomerulonephritis (anti-GBM-GN). Urine and renal tissue MDA levels were markedly elevated in mice with anti-GBM
glomerulonephritis compared with the normal controls. Pretreatment with ()-epigallocatechin-3-gallate (EGCG) normalized the urine
and renal tissue MDA levels. Serum MDA levels were not significantly altered among the three groups. Urinary and renal tissue H2O2 levels
were markedly elevated in mice with anti-GBM-GN compared with the normal control group. Serum H2O2 levels were not significantly
different between the two groups. EGCG pretreatment was associated with a marked reduction of H2O2 levels in the urine, serum, and renal
tissue. Immunohistochemistry showed diffuse and strong nitrotyrosine staining in both vehicle- and EGCG-pretreated animals, but the
staining was much weaker in the normal control mice. Similar results were obtained with western blot analysis for nitrotyrosine performed
on the kidney tissues. Values are expressed as mean±s.e.m. n¼ 7 in each group.
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mild focal p65/NF-kB was expressed in occasional glome-
rular and interstitial infiltrating leukocytes (1þ ) and
scattered tubular epithelial cells (2þ ), with the reactivity
primarily localized to cytoplasm. No significant glomerular
or tubulointerstitial staining was seen in the normal control
mice. Western blot confirmed the immunohistochemical
results, with significantly higher renal p65/NF-kB expression
in the vehicle-pretreated mice than both the EGCG-
pretreated and normal control mice (Figure 6).
Peroxisome proliferator-activated receptor-g (PPARg) antago-
nist GW9662 co-administration reversed the renoprotective effect
of EGCG. To examine whether PPARg pathway is essential
for the renoprotective effect of EGCG, a subgroup of EGCG-
pretreated mice with anti-GBM-GN was concomitantly
administered a selective PPARg antagonist GW9662 (anti-
GBM/EGCGþGW) following the same time schedule
(day 2 to day 14). EGCG pretreatment led to significantly
less proteinuria and normalized serum creatinine compared
with both vehicle-pretreated and EGCGþGW-pretreated
mice, the values in the latter two groups being compa-
rable (Table 2). Both vehicle- and EGCGþGW-pretreated
mice showed moderate to severe renal injury, whereas
the EGCG-pretreated mice exhibited milder renal injury
(Table 2).
Western blot analyses showed significantly lower expres-
sion of PPARg and significantly higher expression of p-Akt
and phosphorylated extracellular signal-regulated kinases 1
and 2 (p-ERK1/2) in the vehicle-pretreated mice compared
with both the normal control and EGCG-pretreated mice
(Figure 7). As expected, co-administration of GW9662
abolished the EGCG-induced upregulation of PPARg. Inter-
estingly, co-administration of GW9662 also abolished the
EGCG-induced inactivation of p-Akt and p-ERK1/2.
EGCG initiated after the development of anti-GBM-GN
ameliorated disease severity
To examine the therapeutic effect of EGCG, subgroups of
anti-GBM antibody injected mice were allowed to develop
severe nephritis before intervention. EGCG treatment was
initiated on day 7 following anti-GBM administration and
continued for 3 weeks (day 7 to day 28). On day 7, both
groups of mice with anti-GBM-GN developed severe GN
evidenced by severe proteinuria and azotemia. At the end of
the 4-week observation period, the vehicle-treated group
suffered a mortality rate of 42% compared with 10% in the
EGCG-treated group. The vehicle-treated mice with anti-
GBM-GN developed renal insufficiency and proteinuria in
contrast to the normal control group on day 28. The EGCG-
treated mice showed significantly less proteinuria and lower
serum creatinine than the vehicle-treated mice (Table 3).
DISCUSSION
Our study shows that pretreating mice with EGCG 2 days
before the induction of anti-GBM-GN leads to a dramatic
and unequivocal improvement in the laboratory and histo-
pathological parameters, evidenced by a significant reduction
in proteinuria and serum creatinine, and improvement
in histological findings including decreased glomerular
crescents, less tubulointerstitial injury, and reduced glome-
rular and interstitial inflammatory cells. More importantly,
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Figure 4 |Western blot analyses of endothelial and inducible nitric oxide synthase (eNOS and iNOS) and measurements of
nitric oxide metabolites (NOX). Western blot showed similar levels of renal eNOS expression in the three groups. In contrast, iNOS
protein content of renal tissue showed a significant rise in the vehicle-pretreated animals compared with both normal control and
()-epigallocatechin-3-gallate (EGCG)-pretreated group. Total nitric oxide metabolites, NO2þNO3 (NOX), in kidney, urine, and serum
were significantly higher in the vehicle-pretreated mice compared with the normal control mice. EGCG pretreatment normalized the total
NOX levels in kidney, urine, and serum. Values are expressed as mean±s.e.m. n¼ 7 in each group.
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administration of EGCG to mice with full-blown anti-GBM-
GN also ameliorates renal injury and reduces mortality rate.
Our data also show that reduced renal disease in EGCG-
pretreated mice was not related to a less severe systemic
immune response to the administered rabbit immunoglobu-
lin because the levels of IgG mouse anti-rabbit antibodies
were comparable between the vehicle- and EGCG-pretreated
mice with anti-GBM-GN. We further demonstrate that
glomerular disease in the mouse model of anti-GBM-GN is
accompanied by oxidative damage as shown by high renal
and urine levels of oxidative stress markers MDA and H2O2.
Pretreatment with EGCG significantly reduced the renal and
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Figure 5 |Reactive oxygen species (ROS)-generating and antioxidant enzymes in mice with anti-glomerular basement membrane
antibody-induced glomerulonephritis (anti-GBM-GN). Western blot showed significantly higher expressions of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase subunit p47phox in vehicle-pretreated mice with anti-GBM-GN compared with both the normal
control and ()-epigallocatechin-3-gallate (EGCG)-pretreated mice. The expression of superoxide dismutase-1 (SOD-1) was significantly
higher in the EGCG-pretreated mice compared with the vehicle-pretreated mice, in which the SOD-1 expression was modestly elevated
compared with the normal controls. The renal tissue glutathione peroxidase (GPx) expression was significantly reduced in vehicle-
pretreated mice and was restored by EGCG supplementation. The expression of myeloperoxidase (MPO) was significantly elevated in the
vehicle-pretreated mice and was normalized by EGCG pretreatment. There was no significant difference in the expressions of heme
oxygenase-1 (HO-1) among the three groups of mice. The renal catalase activity was significantly lower in the vehicle-pretreated mice
compared with both the normal control and EGCG-pretreated mice. Values are expressed as mean±s.e.m. n¼ 7 in each group.
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urine levels of MDA and H2O2 in mice with anti-GBM-GN.
A main source of ROS in inflammatory conditions is
NADPH oxidase, which is abundantly expressed in neutro-
phils and macrophages and responsible for single-electron
reduction of oxygen to superoxide anion. We found a
significant upregulation of the p47phox regulatory subunit of
NADPH oxidase in the vehicle-pretreated mice and its
reversal with EGCG pretreatment, paralleling the changes in
the intensity of inflammatory infiltration found on histo-
logical examination. In addition to reducing the enzyme
abundance, EGCG may inhibit NADPH oxidase activity.15,16
Oxidative stress in immune-mediated GN can also be
caused by impaired capacity of antioxidant system to
inactivate ROS. Despite severe oxidative stress and inflam-
mation, SOD was only slightly upregulated, whereas catalase
and GPx were downregulated in the vehicle-pretreated mice
compared with the normal control mice. The normalization
of renal catalase and GPx levels would be consistent with the
reduced H2O2 levels in EGCG-pretreated mice. Additionally,
EGCG pretreatment was associated with marked upregula-
tion of SOD, as previously shown.17 MPO is abundantly
expressed in the neutrophils and macrophages and converts
H2O2 to highly cytotoxic hypochlorous acid. The markedly
elevated MPO seen in the vehicle-treated mice and
consequent production of hypochlorous acid must contri-
bute to renal injury in this model of immune-mediated GN.
EGCG supplementation has been shown to significantly
attenuate cisplatin-induced renal injury in rats by activating
HO-1.18 However, our data showed no significant changes of
renal HO-1 expression among the three groups of mice,
suggesting that HO-1 does not play a major role in anti-
GBM-GN, and EGCG pretreatment does not significantly
affect HO-1 in this disease model.
Although EGCG pretreatment significantly lowered NO
metabolites in kidney, urine, and serum in mice with anti-
GBM-GN, it did not reduce the kidney tissue abundance of
nitrotyrosine, an indicator of nitrosative stress.19 This might
be because of the limited duration of the study, as
disappearance of the preformed nitrotyrosine would depend
on the turnover of proteins with nitrated tyrosine residues.
The similar expression of eNOS in all three groups suggests
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Figure 6 |Western blot analysis and immunolocalization of
osteopontin and p65/nuclear factor-jB (NF-jB) in renal
tissues from mice with anti-glomerular basement membrane
antibody-induced glomerulonephritis (anti-GBM-GN) and
normal controls. Immunohistochemical analysis showed marked
upregulation of osteopontin and p65/NF-kB in the vehicle-
pretreated animals compared with the ()-epigallocatechin-3-
gallate (EGCG)-pretreated and normal control groups. The vehicle-
pretreated animals showed diffuse osteopontin and p65/NF-kB
expressions in renal tubules, resident glomerular cells, and
infiltrating leukocyte in glomeruli and interstitium. The above
findings were confirmed by western blot analyses. For western blot
analyses, values are expressed as mean±s.e.m. n¼ 7 in each group.
Table 2 | Peroxisome proliferator-activated receptor-c (PPARc) modulates the renoprotective effect of EGCG
Control Anti-GBM/vehicle Anti-GBM/EGCG Anti-GBM/EGCG+GW
Body weight (g) 19.2±0.5 16.7±0.6* 19.3±0.3# 18.2±0.7
Serum creatinine (mg/dl) 0.073±0.004 0.138±0.018** 0.079±0.007## 0.131±0.024**,w
Proteinuria (mg per 24 h) 0.69±0.13 12.45±2.51** 5.66±1.9#,** 11.89±1.10**,w
Glomerulonephritis score (0–4) 0±0 3.5±0.2** 1.8±0.6#,* 3.6±0.3**,w
Crescents (%) 0±0 25.0±5.8** 2.6±1.9##,* 43.5±11.9**,w
Tubulointerstitial injury score (0–5) 0±0 2.4±0.2** 0.7±0.4#,* 2.7±0.4**,w
Abbreviations: Anti-GBM/EGCG, anti-glomerular basement membrane antibody-induced glomerulonephritis pretreated with () epigallocatechin-3-gallate; anti-GBM/
EGCG+GW, anti-glomerular basement membrane antibody-induced glomerulonephritis pretreated concomitantly with () epigallocatechin-3-gallate and PPARg antagonist
GW9662; anti-GBM/Vehicle, anti-glomerular basement membrane antibody-induced glomerulonephritis pretreated with vehicle.
Values are mean±s.e.m.; n=6 or 7 in each group.
*Po0.05, **Po0.01 vs normal control.
#Po0.05, ##Po0.01 vs anti-GBM/vehicle.
wPo0.05 vs anti-GBM/EGCG.
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that the increased levels of NO metabolites in the vehicle-
treated mice with anti-GBM-GN is unrelated to eNOS
activity and must be because of the observed upregulation of
iNOS. Similarly, the reduction in the level of NO metabolites
in the EGCG-pretreated mice appears to be because of
downregulation of iNOS. Accordingly, increased NO produc-
tion and the associated nitrosative stress in anti-GBM-GN is
because of the induction of iNOS in inflammatory and
resident cells.20 This is supported by parallel reductions of
iNOS and inflammatory cells in kidneys of the EGCG-
pretreated mice. In addition, direct removal of peroxynitrite
and other reactive nitrogen species by EGCG may have
contributed to the reduction of tissue and urinary NO
metabolites.21
NF-kB plays a critical regulatory role in inflammation and
immune responses and its activation has been implicated in
experimental GN.22–24 In the vehicle-pretreated mice, there
was diffuse and strong p65/NF-kB expression in renal cortex
with the immunoreactivity localized both in cytoplasm and
nucleus, the latter signifying NF-kB activation. Conversely, in
the EGCG-pretreated mice, there was mild focal p65/NF-kB
expression primarily in the cytoplasm. These results are
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Figure 7 |Western blot analyses of peroxisome proliferator-
activated receptor-c (PPARc), phosphorylated extracellular
signal-regulated kinases 1 and 2 (p-ERK1/2), and p-Akt
in renal tissues from mice with anti-glomerular basement
membrane antibody-induced glomerulonephritis
(anti-GBM-GN) and normal control. To examine whether
PPARg pathway is essential for the renoprotective effect of
()-epigallocatechin-3-gallate (EGCG), a subgroup of EGCG-
pretreated mice with anti-GBM-GN was concomitantly
administered with a selective PPARg antagonist GW9662
following the same time schedule (day 2 to day 14). Western
blot analyses showed significantly lower expression of PPARg in
the vehicle-pretreated mice compared with both the normal
control and EGCG-pretreated mice. Co-administration of GW9662
abolished the EGCG-induced upregulation of PPARg. Western blot
analyses showed significantly higher expression of p-Akt and
ERK1/2 in the vehicle-pretreated mice compared with both the
normal control mice and EGCG-pretreated mice. Interestingly,
co-administration of GW9662 abolished the EGCG-induced
inactivation of p-Akt and p-ERK1/2. Values are expressed as
mean±s.e.m. n¼ 7 in each group.
Table 3 | EGCG administration after the development of
anti-GBM-GN ameliorates disease severity
Control
(n=8)
Anti-GBM/
vehicle (n=12)
Anti-GBM/
EGCG (n=10)
Body weight (g)
Baseline 19.8±0.3 20.0±0.5 19.6±0.4
Day 28 20.0±0.2 19.4±0.5 19.0±0.5
Serum creatinine (mg/dl)
Baseline 0.073±0.004 0.071±0.003 0.074±0.004
Day 7 0.077±0.005 0.181±0.033** 0.153±0.058**
Day 28 0.086±0.007 0.274±0.044** 0.151±0.043*,#
Proteinuria (mg per 24 h)
Baseline 0.61±0.07 0.73±0.13 0.64±0.12
Day 7 0.74±0.12 14.47±2.39** 13.28±2.73**
Day 28 0.67±0.14 13.06±2.15** 6.62±1.53*,#
Number of death/
mortality rate
0/0% 5/42%** 1/10%*,#
Abbreviations: Anti-GBM/EGCG, () epigallocatechin-3-gallate treatment started
7 days after the induction of anti-glomerular basement membrane glomerulone-
phritis; anti-GBM/vehicle, vehicle started 7 days after induction of anti-glomerular
basement membrane glomerulonephritis; GN, glomerulonephritis.
Values are mean±s.e.m.
*Po0.05, **Po0.01 vs normal control.
#Po0.05 vs anti-GBM/vehicle.
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consistent with the reported inhibitory effects of EGCG on
NF-kB, such as in a rat model of diabetic nephropathy.25
Normally, translocation of NF-kB to the nucleus is prevented
by binding to its inhibitor, IkB. Phosphorylation of IkB by
IkB kinase causes ubiquitination and degradation of IkB and
translocation of NF-kB to the nucleus.26 This process is
triggered by ROS and inflammatory cytokines, accounting for
the observed changes in NF-kB distribution in our vehicle-
and EGCG-pretreated animals. In addition, EGCG may
decrease IkB kinase activity, thereby blocking nuclear
translocation of NF-kB and expression of its downstream
gene products including iNOS.27
OPN is a secreted phosphoprotein and chemokine that
promotes formation and progression of crescentic GN in
human and animal models.28–31 Our vehicle-pretreated mice
showed diffuse and strong OPN expression, whereas mild
and focal OPN expression was noted in the EGCG-pretreated
mice. As expression of this chemokine is induced by
inflammation, our observations reflect florid inflammation
in the vehicle-pretreated mice and its attenuation with EGCG
pretreatment.
PPARg belongs to a family of nuclear hormone receptors
with protective role in kidney diseases.32 PPARg agonists
attenuate nephropathy in experimental models of anti-GBM-
GN,33 lupus erythematosus, type 2 diabetes, and nondiabetic
glomerulosclerosis, and decrease proteinuria in patients with
type 2 diabetes and nondiabetic renal disease.34–38 Our study
shows that PPARg expression is downregulated in mice with
anti-GBM-GN and is restored by EGCG pretreatment.
Furthermore, concomitant administration of EGCG with a
selective PPARg antagonist GW9662 prevented the EGCG-
induced upregulation of PPARg and reversed the renopro-
tective effect of EGCG, pointing to the essential role of
PPARg pathway in mediating the anti-inflammatory capacity
of EGCG. It has been shown that EGCG inhibits the mitogen-
activated protein kinase pathways and that pretreatment with
EGCG prevents ultraviolet B-induced H2O2 production and
inhibits ultraviolet B-induced phosphorylation of ERK1/2,
c-Jun N-terminal kinase, and p38 in cultured human
epidermal keratinocytes.39 Therefore, restoration of renal
PPARg expression by EGCG may be related to suppression of
ERK1/2 activation, which is consistent with the observed
reduction of p-ERK1/2 in EGCG-pretreated mice. Addition-
ally, inhibition of mitogen-activated protein kinases by
EGCG could inhibit the phosphatidylinositol 3-kinase/Akt
pathway,26 which is consistent with the observed reduction of
p-Akt in the EGCG-pretreated mice. This is also supported
by a recent study showing attenuation of inflammation in
MRL/lpr mouse mesangial cells via inhibition of the Akt
pathway by EGCG.40
In summary, our data suggest that EGCG ameliorates
laboratory and histological abnormalities in this mouse
model of immune-mediated GN. These salutary effects of
EGCG are likely mediated by its anti-inflammatory and
antioxidative properties. These observations demonstrate the
potential utility of EGCG as a therapeutic agent for the
treatment of immune-mediated GN and other immune-
mediated diseases.
MATERIALS AND METHODS
Animal model and experimental design
Anti-GBM serum was generated by Lampire Laboratories
(Pipersville, PA).41,42 Preimmune rabbit serum was used as negative
control. All studies were reviewed and approved by the institutional
review committee at UT Southwestern. Anti-GBM-GN was induced
in male 129/svJ mice (Jackson Laboratories, Bar Harbor, ME).41–44
Briefly, 40 8-week-old mice were presensitized on day 5 (5 days
before inducing anti-GBM-GN) with rabbit IgG (120mg per mouse)
in complete Freund’s adjuvant (Sigma, St Louis, MO). On day 0, the
mice received anti-GBM serum; 120 mg of total IgG in a 100ml
volume was administered intravenously. This dosing regimen was
sufficient to induce proteinuria but not mortality. All mice were
maintained in a specific pathogen-free colony.
Anti-GBM antibody injected mice were randomly assigned to
either the vehicle or EGCG-pretreated (Sigma-Aldrich, St Louis,
MO) group. The latter group (n¼ 14) received 50mg/kg/day45 of
EGCG orally initiated on day 2 (2 days before inducing anti-GBM-
GN) and continued until killing on day 15. Normal saline was given
to the vehicle group (n¼ 14) with the same protocol. A group
(n¼ 14) without anti-GBM antibody or EGCG administration was
included as normal control. On day 5 (baseline) and on day 14,
sera and 24-h urine samples were collected from all mice using
metabolic cages, with free access to drinking water. All animals were
killed on day 15. The kidneys were processed for further analyses
described below.
A subgroup of EGCG-pretreated mice with anti-GBM-GN was
concomitantly administered a selective PPARg antagonist GW9662
(Sigma) following the same schedule (day 2 to day 14).
To explore the therapeutic effect of EGCG, 22 anti-GBM
antibody-injected mice were allowed to develop full-blown nephritis
(for 7 days) before intervention. In order to produce more severe
GN, the mice received a higher dose of anti-GBM serum (140 mg of
total IgG per mouse). On day 7 following anti-GBM administration,
the mice were randomized into either EGCG- or vehicle-treated
group. The former group (n¼ 10) received 50mg/kg/day of EGCG
orally (gavage) for 3 weeks (day 7 to day 28) until killing on day 29.
Normal saline was given to the vehicle group (n¼ 12) with the same
protocol. A group (n¼ 8) without anti-GBM antibody or EGCG
administration was included as normal control. On days 7 and 28,
sera and 24-h urine samples were collected from all mice. All
animals were killed on day 29.
Measurement of urine protein and serum creatinine
All urine samples were centrifuged at 14,000 r.p.m. for 5min. Clear
supernatant was used for urine protein assay (Coomassie Plus
protein assay kit, Cat. no. 23236; Pierce, Rockford, IL). The serum
creatinine levels were measured as previously described.46
Measurement of systemic immune response to injected
anti-GBM antibodies
Mouse antibodies to rabbit immunoglobulin were assayed by
enzyme-linked immunosorbent assay as described previously.42
Briefly, purified rabbit Ig (Sigma) was coated onto Immulon I
plates (Dynatech, Chantilly, CA) and then blocked. Serially diluted
mouse sera were added to the plates and any bound mouse anti-
rabbit Ig was detected using alkaline-phosphatase-conjugated goat
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anti-mouse IgG (Roche, Branchburg, NJ) that did not crossreactive
with rabbit Ig and P-nitrophenyl phosphate substrate (Sigma). Color
development was measured spectrophotometrically at 405 nm. All
assays were run in duplicate, and samples were reanalyzed when
standard errors 410% were found.
Measurement of markers of oxidative stress and antioxidant
system
Total concentration of NO metabolites in serum, urine, and renal
cortical tissue was determined with the QuantiChrom Nitric Oxide
Assay Kit (BioAssay Systems, Hayward, CA).42 Renal tissue samples
were first rinsed with phosphate-buffered saline (pH 7.4, containing
0.1mg/ml heparin) three times to remove red blood cells and clots.
Catalase activity in renal tissue was measured with the catalase
assay kit (ab83464; Abcam, Cambridge, MA) according to the
manufacturer’s protocol. Renal tissue was homogenized in 200 ml
cold assay buffer and centrifuged for 10min at 14,000 r.p.m. Clear
supernatant was used for the assay.
H2O2 was determined in urine and renal tissue with peroxide
assay kit of BioAssay Systems that utilizes the chromogenic
Fe3þ -xylenol orange reaction, in which a purple complex is formed
when Fe2þ is oxidized to Fe3þ by H2O2. The intensity of the color
(at 540–610 nm) is an accurate measure of the H2O2 level.
Lipoperoxides in serum, urine, and renal tissue were determined
by measurement of malondialdehyde-thiobarbituric acid with a
TBARS assay kit (Cat. no. 10009055; Cayman Chemical Company,
Ann Arbor, MI), according to the manufacturer’s protocol.
Renal histopathology and immunohistochemistry
Next, 3mm sections of formalin-fixed and paraffin-embedded kidney
tissues were cut and stained with hematoxylin and eosin and periodic
acid-Schiff reaction. These sections were examined in a blinded fashion.
The GN was graded on 0–4 scale and the tubulointerstitial injury was
graded on 0–5 scale, as detailed previously.42,47
The numbers of intrarenal leukocytes within the glomeruli and
interstitium were counted by staining formalin-fixed and paraffin-
embedded tissue sections with antibodies to lymphocytes (CD3,
Cat. no. MCA1477, 1:500; AbD Serotec, Raleigh, NC) and macrophages
(Iba1, Cat. no. 019-19741, 1:500; Wako Chemicals, Richmond, VA). The
expression and localization of p65/NF-kB (Cat. no. SC-109, 1:200; Santa
Cruz Biotechnology, Santa Cruz, CA), OPN (Cat. no. SC-21742, 1:200;
Santa Cruz Biotechnology), and nitrotyrosine (Cat. no. SC-101358,
1:200; Santa Cruz) were also evaluated. Standard avidin-biotin complex
method was used for immunohistochemical staining, which was
estimated from 0 to 3 as described previously.47
Western blot
Western blotting was performed as previously described.48 Briefly,
40mg total protein was size-fractionated and transferred onto
nitrocellulose membrane (Hybond-ECL; Amersham, Buckinghamshire,
UK) at 350mA for 2.5 h using the Mini Trans-Blot system (Bio-Rad,
Hercules, CA). The membrane was prehybridized in 10ml blocking
buffer (1 Tris buffered saline, 0.1% Tween-20, and 5% nonfat
milk powder) for 1 h and then hybridized overnight at 4 1C with the
following primary antibodies (diluted with the same buffer): anti-
eNOS (Cat. no. 610296, 1:5000; BD Biosciences, San Jose, CA), anti-
iNOS (Cat. no. ab3523, 1:2000; Abcam), anti-nitrotyrosine (1:2000),
anti-p65/NF-kB (1:2000), anti-phosphorylated Akt (Ser 473, 1:1000;
Cell Signaling, Danvers, MA), anti-phosphorylated ERK1/2
(Thr202/Tyr204, 1:1000, Cat. no. 9101), anti-HO-1 (Cat. no.
ab13243, 1:5000; Abcam), anti-PPARg (Cat. no. ab19481, 1:1000;
Abcam), anti-NADPH oxidase p47phox (Cat. no. SC-14015, 1:500;
Santa Cruz), anti-SOD-1 (Cat. no. sc-271014, 1:1000; Santa Cruz),
anti-MPO (Cat. no. ab45977, 1:1000; Abcam), or anti-GPx1 (Cat.
no. ab22604, 1:5000; Abcam). The membrane was washed for
30min in a shaking bath (the wash buffer, Tris-buffered saline and
Tween-20, was changed three times every 10min) and then
incubated for 1 h with block buffer plus anti-mouse or anti-rabbit
IgG tagged with horseradish peroxidase at a final titer of 1:5000. The
washes were repeated before the membrane was developed with a
light emitting nonradioactive ECL reagent (SuperSignal West Dura
kit; Thermo Scientific, Rockford, IL) and subjected to autolumino-
graphy for 5min. The band intensities were measured using Scion
Image (WinB403; http://rsb.info.nih.gov/nih-image/).
Statistical analyses
Data are presented as mean±s.e.m. Analysis of variance, Fisher’s
exact test, and Student’s t-test were used in statistical evaluation as
appropriate. The P-values of p0.05 were considered significant.
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